Is Hormone Replacement Therapy (HRT) Safe?

At the turn of the 21st century a shocking study was released that changed healthcare. You've probably heard the headlines. "Hormones cause cancer." "Hormones are dangerous." Maybe your mother was told to stop her hormones cold turkey, and the fear has lingered ever since. After discussing why this happened, we will walk through what today’s science actually says about HRT, also known as menopausal hormone therapy (MHT). The situation is far more nuanced and hopeful than the story you may have been told.

The Study That Changed Everything (and got it wrong)

In 2002, a massive study called the Women's Health Initiative (WHI) made international headlines. The study was actually halted before its completion so that patients could be removed from hormone therapy and warnings could be broadcast to the healthcare community. The takeaway that spread like wildfire: hormone therapy is dangerous [1]. 

Here's what most people never understood: the average age of women in that study was 63. Many were a decade or more past menopause where the dangers of starting on hormone therapy are much greater. Some had pre-existing health conditions. That's a very different demographic from a 51-year-old woman in the thick of hot flashes, brain fog, and sleepless nights who is considering hormone therapy. 

The study also only addressed women using oral estrogen attained from the urine of pregnant horses. Today Women have access to much safer forms of estrogen, like bio-identical estradial and transdermal applications [6].

Since then, researchers have spent over two decades re-analyzing that data and conducting new studies. The picture that has emerged is dramatically different from those early headlines. For most healthy women in menopause, the benefits of hormone therapy generally outweigh the risks; and the absolute risks are small [4].

Here's what the most recent data indicates:

Heart Health: Timing Is Everything

One of the most important discoveries is what researchers call the "timing hypothesis" or the "window of opportunity." This states, that when hormone therapy is started before age 60 or within 10 years of menopause:

• Coronary heart disease risk is not increased and may actually be reduced by roughly 50% compared to placebo [5].

• Stroke rates in women aged 50–59 were identical between hormone therapy and placebo [1].

• All-cause mortality may be reduced by approximately 30% [4].

When starting after age 60 or more than 10 years past menopause, the cardiovascular picture is less favorable, with increased risks of stroke and blood clots. This is why timing matters so much [5].

Breast Cancer: The Part Everyone Worries About

This is the question that keeps women up at night, so let's break it down clearly. The risk depends heavily on the type of hormone therapy:

• Estrogen alone (given to women who've had a hysterectomy): In the WHI, estrogen-only therapy was actually associated with a lower risk of breast cancer: about a 22% reduction in incidence and a 40% reduction in breast cancer death over long-term follow-up. That's right, lower, not higher [2].

• Estrogen plus a progestogen (needed if you still have your uterus): Combined therapy was associated with a modest increase in breast cancer risk: about 1 extra case per 1,000 women per year. To put that in perspective, that's a smaller increase in risk than drinking one glass of wine daily or being obese [3].

The type of progestogen may also matter. Observational studies suggest that micronized progesterone (a body-identical form) may carry a more favorable breast cancer profile than some older synthetic progestins, though this hasn't been confirmed in large randomized trials [8].

Blood Clots: Risk Lower with Transdermal Route.

Oral hormone therapy does increase the risk of blood clots, which can lead to venous thromboembolism and stroke; though the absolute risk is small in younger, healthy women (about 1 extra event per 1,000 women per year.) [4]

Transdermal estrogen (patches, gels, sprays) appears to have a much lower impact on clotting risk compared to pills, because it bypasses the liver [9]. Many menopause specialists now prefer transdermal delivery for this reason.

The Benefits Beyond Hot Flashes

Hormone therapy isn't just about stopping hot flashes (though it does that better than anything else: reducing them by about 75% [6]). The data also shows:

• Significant reduction in bone fractures - roughly 25–30% fewer fractures across the board [4]

• Improvement in genitourinary symptoms like vaginal dryness, painful intercourse, and urinary issues [6]

• Reduced risk of type 2 diabetes during active use [6]

• Potential reduction in colorectal cancer risk with combined therapy (estrogen+progesterone) [4]

• Meaningful improvements in sleep, mood, and quality of life [6]

For women with premature or early menopause (before age 45), hormone therapy is strongly recommended until at least the typical age of menopause to protect bone, brain and cardiovascular health [6].

What the Major Medical Societies Say

The North American Menopause Society, the American College of Obstetricians and Gynecologists, and the UK's NICE guidelines all agree: hormone therapy remains the most effective treatment for bothersome menopausal symptoms. They recommend it be [6]:

• individualized for each patient

• used at the lowest effective dose

• continued for as long as benefits outweigh risks (no arbitrary age-based cutoff for stopping)

The US Preventive Services Task Force does recommend against using hormone therapy solely to prevent chronic diseases like heart disease [7]. But that's a different situation from using it to treat menopause symptoms that are disrupting your life, and getting a little cardio-protective benefits on the side.

What About "Bioidentical" Hormones?

FDA-approved "body-identical" hormones such as estradiol patches and micronized progesterone capsules are available by prescription and have been studied in clinical trials. These are what most menopause specialists prescribe today [6, 8].

Custom-compounded "bioidentical" hormones from compounding pharmacies are a different story. They are not FDA-regulated, may have inconsistent dosing, and lack the safety data of FDA-approved products. The major medical societies do not recommend them over FDA-approved options [6].

What This Means For You

Hormone therapy is not a one-size-fits-all decision. For healthy women in early menopause with bothersome symptoms, the data in 2026 is reassuring:

• The absolute risks are small. Generally less than 1 adverse event per 1,000 women per year for those who start HRT early [3]

• Risk can be reduced by timing, type, dose, and route of delivery [5, 9]

• The benefits are real and meaningful: from symptom relief to bone & heart protection [6]

Individualized care with a knowledgeable menopause society certified practitioner is key. You don't have to suffer through menopause because of a misleading study from 2002. You deserve a conversation based on today's evidence, not yesterday's fears.

If you're wondering whether hormone therapy might be right for you, we're here to help you weigh the evidence, understand your personal risk factors, and make a decision that feels right for your body and your life. Book your free discovery call today.

---

References

1. Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748–1760. https://doi.org/10.1001/jama.2024.6542

2. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-Term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369–380. https://doi.org/10.1001/jama.2020.9482

3. Collaborative Group on Hormonal Factors in Breast Cancer. Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence. Lancet. 2019;394(10204):1159–1168. https://pubmed.ncbi.nlm.nih.gov/31474332/

4. Bofill Rodriguez M, Yong LN, Mirkov S, et al. Long-Term Hormone Therapy for Perimenopausal and Postmenopausal Women. Cochrane Database of Systematic Reviews. 2025;11:CD004143. https://doi.org/10.1002/14651858.CD004143.pub6

5. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. Circulation. 2020;142(25):e506–e532. https://doi.org/10.1161/CIR.0000000000000912

6. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405–420. https://doi.org/10.1001/jama.2022.24140

7. Mangione CM, Barry MJ, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons. JAMA. 2022;328(17):1740–1746. https://doi.org/10.1001/jama.2022.18625

8. Gompel A, Simcock R. Menopausal Hormone Treatment and Breast Cancer. Lancet Diabetes Endocrinology. 2026;14(3):259–274. https://doi.org/10.1016/S2213-8587(25)00394-8

9. Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018;21(4):341–345. https://pubmed.ncbi.nlm.nih.gov/29570359/

This content is for educational purposes only and is not a substitute for personalized medical advice. Consult your healthcare provider for guidance specific to your situation.